Richard M. Stone, MD | Authors

Articles

Monitoring MRD in Patients with AML

October 30, 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).